Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review

McLernon, David J.; Dillon, John; Donnan, Peter T.

doi:10.1177/0272989x08315240

Cited by 147 publications

(116 citation statements)

References 54 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…5,[16][17][18]20,[22][23][24][25][26][27][28][29][30][31][32] All cost data were expressed in Canadian dollars and were inflated to 2015 using the Statistics Canada Consumer Price Index for health care and personal items. 33 Treatment efficacy and safety inputs were generated directly from the network meta-analysis model.…”

Section: Model Parametersmentioning

confidence: 99%

Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis

et al. 2017

View full text Add to dashboard Cite

Section: Model Parametersmentioning

confidence: 99%

Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis

et al. 2017

View full text Add to dashboard Cite

“…*The study 47 did not include patients with decompensated cirrhosis, so utility for these patients was determined by adjusting the chronic HCV infection utility score according to a disutility value published in the systematic review. 48 approach resulted in a net cost increment of $266 and 0.0077 QALYs gained per person, which translated to an incremental cost-effectiveness ratio of $34 783 per QALY gained (Table 3). We repeated the 4 screening strategies by considering 1-time screening for individuals 45-64 years of age.…”

Section: Model Validationmentioning

confidence: 99%

Cost-effectiveness of screening for hepatitis C in Canada

Wong

Feld

et al. 2015

CMAJ

View full text Add to dashboard Cite

Background:The seroprevalence of hepatitis C virus (HCV) infection among Canadians is estimated at 0.3% to 0.9%. Of those with chronic HCV infection, 10% to 20% will experience advanced liver disease by 30 years of infection. Targeted screening seems a plausible strategy. We aimed to estimate the health and economic effects of various screening and treatment strategies for chronic HCV infection in Canada. Methods:We used a state-transition model to examine the cost-effectiveness of 4 screening strategies: no screening; screen and treat with pegylated interferon plus ribavarin; screen and treat with pegylated interferon and ribavarinbased direct-acting antiviral agents; and screen and treat with interferon-free direct-acting antivirals. We considered Can adian residents in 2 age groups: 25-64 and 45-64 years of age. We obtained model data from the literature. We predicted deaths related to chronic HCV infection, costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios. Results:We found that screening and treating would prevent at least 9 HCV-related deaths per 10 000 persons screened over the lifetime of the cohort. Screening was associated with QALY increases of 0.0032 to 0.0095 and cost increases of $124 to $338 per person, which translated to an incremental cost-effectiveness ratio of $34 359 to $44 034 per QALY gained, relative to no screening, depending on age group screened and antiviral therapy received.Interpretation: A selective one-time HCV screening program for people 25-64 or 45-64 years of age in Canada would likely be cost-effective. Identification of silent cases of chronic HCV infection and the offer of treatment when appropriate could extend the lives of Canadians at reasonable cost. Abstract Research E111CMAJ, February 17, 2015, 187(3)

show abstract

“…In response to Cortese et al, we clarify that in our analysis we used utilities reported in table 1 of our study 1 and that were similar to those reported in a meta-analysis by McLernon et al 6 using the EQ-5D. Specifically, the utilities we used were those reported by Sullivan et al, 7 and not by Liu et al, 8 as wrongly reported due to a misprint.…”

Section: Cost-effectiveness Analysis Of New Drugs For Chronic Hepatitmentioning

confidence: 73%